Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer

Peking Union Medical College Hospital3,705 enrolled

Overview

The purpose of this study is to compare the efficacy, prognosis, health economics of different treatment modalities of mid-low rectal cancer in different centers in China, and to conduct cost utility analysis (CUA) on the treatment process of rectal cancer to explore the best treatment modality that meets the actual need of medical units in each region and at each level. The investigators hope to provide evidence-based medical suggestions for medical quality control of rectal cancer and revision of clinical guidelines, and provides a source of decision making for medical management and medical insurance.

Study Type

OBSERVATIONAL

Enrollment

3,705

Conditions

Rectal Neoplasms

Interventions

Registry study, no specific interventionOTHER

Registry study, no specific intervention

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * pathologically confirmed rectal adenocarcinoma * located within 12cm below the anal verge Exclusion Criteria: * diagnosed with distant metastasis * multiple primary colorectal cancers * history of previous malignant tumors * Pregnant or lactating women

Outcomes

Primary Outcomes

3-year OS

3-year overall survival

Time frame: 3 years

Secondary Outcomes

3-year DFS

3-year disease-free survival

Time frame: 3 years

3-year LR

3-year local recurrence rate

Time frame: 3 years

3-year distant metastasis rate

Time frame: 3 years

neoadjuvant therapy rate

the percentage of patients who underwent standard neoadjuvant therapy

Time frame: at the time point of surgery of the primary lesion

adjuvant therapy rate

the percentage of patients who underwent standard adjuvant therapy

Time frame: at the time point of 3-year follow up

EUS/MRI assessment rate

the percentage of patients who underwent standard rectal EUS/MRI assessment

Time frame: at the time point of surgery of the primary lesion

R0 resection rate

the percentage of patients who underwent R0 resection

Time frame: at the time point of surgery of the primary lesion

CCR

Clinical Complete Response

Time frame: immediately after the completion of neoadjuvant therapy assessment

pCR

Pathologic Complete Response

Time frame: immediately after the completion of surgery

30-day mortality

death occurring within 30 days of the surgery

Time frame: 30 days after the surgery

Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts